Recent Updates
Recently added Catalysts
INO Positive Sentiment

INOVIO to Participate in Upcoming Investor Conferences

Key Takeaway: INOVIO will participate in two upcoming investor conferences, including the Cantor Global Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference. The events will feature presentations and one-on-one meetings with investors. Replays of the presentations will be available for 90 days after the events.

Market Sentiment Analysis

POSITIVE FACTORS

  • INOVIO is actively participating in key investor conferences.
  • The company is focused on innovative DNA medicines for serious health issues.
  • Management team will engage directly with investors, enhancing transparency.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~6 mo
High dilution risk
Lead asset
VGX-410
Phase 2 · Hepatitis C Virus Infection

Full Press Release Details

PLYMOUTH MEETING, Pa., Sept. 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in the following investor conferences:
Cantor Global Healthcare Conference (New York) Date: Wednesday, September 9 Fireside Chat: 3:20 PM ET Webcast: https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=99315971&checkCompany=1&checkEmail=1&checkName=1
H.C. Wainwright 28 th Annual Global Investment Conference (New York) Presentation Available: Beginning Friday, September 11, 7:00 AM ET Format: Virtual Link: https://journey.ct.events/view/eb47953c-3213-432d-92ca-13beb55c97ae
Replays of the investor presentations will be available for 90 days at the links above. During these conferences members of INOVIO's management team will also be conducting one-on-one meetings with investors.
About INOVIO INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts Media: Jennie Willson, (267) 429-8567, [email protected] Investors: Peter Vozzo, ICR Healthcare, (443) 213-0505, [email protected]

Frequently Asked Questions

What conferences will INOVIO participate in?

INOVIO will participate in the Cantor Global Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference.

When is the Cantor Global Healthcare Conference?

The Cantor Global Healthcare Conference is scheduled for September 9, 2026.

How can I access the investor presentations?

Investor presentations will be available for replay for 90 days at the provided links.

What is INOVIO's focus as a biotechnology company?

INOVIO focuses on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases.

Last updated: Sep 1, 2026